Tag: Vaccine Production

Sanofi and Nanolek Begin Localisation of Menactra Vaccine

Sanofi and Nanolek announced a new stage in the development of a long-term partnership - the beginning of a project to localize the production of Menactra® vaccine. The partnership will help expand th...

Russia Capable of Replacing Complete Volume of Foreign Vaccines Against Influenza

The Natsimbio holding of Rostec State Corporation has begun the second phase of the supply of vaccines for the prevention of influenza in the Russian Federation. Currently, 70% of the contracted volum...

GSK Vaccines to be Produced at NANOLEK’s Facilities

GSK International Research Pharmaceutical Company and Russian biopharmaceutical company NANOLEK announced a long-term strategic partnership, under which GSK vaccines will be produced at NANOLEK's faci...

Russia Announced Start of Vaccination with New Quadrivalent Influenza Vaccine

influenza vaccine
The head of Russia’s Ministry of Health, Veronika Skvortsova, announced the start of vaccination with a new quadrivalent influenza vaccine of high-risk groups, and by 2023 the Ministry plans to comple...

Nanolek to Complete Sanofi Vaccine Localization by 2022

Nanolek plans to launch the full-cycle production of a 5-in-1 infant vaccine under a technology transfer project with Sanofi Pasteur (France) by 2022. The first phase in the project to localize the...

Seqirus seeks European approval for its influenza vaccine

Seqirus, a global leader in influenza prevention, announced that its cell-based quadrivalent influenza vaccine has received a positive opinion from the European Medicines Agency (EMA).

Chinese vaccine manufacturer is fined $1.3 billion

Chinese manufacturer of rabies vaccine was fined 9.1 billion yuan ($1.3 billion) for falsifying production records in a scandal that prompted a nationwide crackdown on the industry.

The production of a quadrivalent influenza vaccine was launched in Podolsk

The vaccine was registered in 2018 and became Russia's first quadrivalent influenza vaccine - it protects against two influenza A virus infection (H1N1 and H3N2) and two influenza B virus infection.

The European Investment Bank provided a €30 million loan for Bavarian Nordic

Bavarian Nordic announced the securing of a loan facility of €30 million from the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States.

Chinese drug regulator launches investigation of all vaccine manufacturers

The National Drug Administration of China (CNDA) launched a thorough investigation into all vaccine producers across the country. Chinese drug producer had violated standards in making of DPT vaccine.

The Russian government will fund the reconstruction of Microgen

The Russian government decided to provide a subsidy from the federal budget to NPO Microgen for the reconstruction and technical re-equipment of its production facilities for influenza vaccines in 2018-2021.

Kirov pharma cluster participants explored biotech development in France

The delegation of the government of the Kirov region visited the Lyonbiopôle in France, which is largest pharmaceutical cluster in the world.

FORT increases its sales of influenza vaccine

In 2018, FORT, a biopharmaceutical company which is part of Marathon Group and Nacimbio (Rostec Corporation), doubled its yoy sales of Ultrex, an influenza vaccine.

Nacimbio supplied more than 1 million doses of TBE vaccine

In January - May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

Russia will have its first quadrivalent influenza vaccine

According to the experts, this vaccine has not only the most effective and safe profile possible today, but also provides undeniable pharmacoeconomic advantages.

Today’s realities in the development of local and contract manufacturing

The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing.